162 related articles for article (PubMed ID: 32954565)
1. Navigating stormy waters: 10 years of operation of the European Union Regulatory Network Incident Management Plan for Medicines for Human Use.
Santoro A; Caplanusi I; Sweeney F; Cappelli B; Nolan L; Straus S; Arlett P
Pharmacoepidemiol Drug Saf; 2020 Nov; 29(11):1343-1352. PubMed ID: 32954565
[TBL] [Abstract][Full Text] [Related]
2. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
3. Improving the Safety of Medicines in the European Union: From Signals to Action.
Potts J; Genov G; Segec A; Raine J; Straus S; Arlett P
Clin Pharmacol Ther; 2020 Mar; 107(3):521-529. PubMed ID: 31621897
[TBL] [Abstract][Full Text] [Related]
4. Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns.
Holm JEJ; Ruppert JG; Ramsden SD
Pharmaceut Med; 2022 Feb; 36(1):33-46. PubMed ID: 35099785
[TBL] [Abstract][Full Text] [Related]
5. Risk minimization activities of centrally authorized products in the EU: a descriptive study.
Zomerdijk IM; Sayed-Tabatabaei FA; Trifirò G; Blackburn SC; Sturkenboom MC; Straus SM
Drug Saf; 2012 Apr; 35(4):299-314. PubMed ID: 22339506
[TBL] [Abstract][Full Text] [Related]
6. Enhancing Pharmacovigilance Capabilities in the EU Regulatory Network: The SCOPE Joint Action.
Radecka A; Loughlin L; Foy M; de Ferraz Guimaraes MV; Sarinic VM; Di Giusti MD; Lesicar M; Straus S; Montero D; Pallos J; Ivanovic J; Raine J
Drug Saf; 2018 Dec; 41(12):1285-1302. PubMed ID: 30128638
[TBL] [Abstract][Full Text] [Related]
7. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight.
Engel P; Almas MF; De Bruin ML; Starzyk K; Blackburn S; Dreyer NA
Br J Clin Pharmacol; 2017 Apr; 83(4):884-893. PubMed ID: 27780289
[TBL] [Abstract][Full Text] [Related]
8. EU's new pharmacovigilance legislation: considerations for biosimilars.
Calvo B; Zuñiga L
Drug Saf; 2014 Jan; 37(1):9-18. PubMed ID: 24190573
[TBL] [Abstract][Full Text] [Related]
9. Interest of pharmacoepidemiology in pharmacovigilance: Post-authorization safety studies in regulatory pharmacovigilance activity.
Abou Taam M; Ferard C; Rocle P; Maison P
Therapie; 2019 Apr; 74(2):301-306. PubMed ID: 30704766
[TBL] [Abstract][Full Text] [Related]
10. Regulatory experience of handling Risk Management Plans (RMPs) for medicinal products in the EU.
Butler D; Vucic K; Straus S; Cupelli A; Micallef B; Serracino-Inglott A; Borg JJ
Expert Opin Drug Saf; 2021 Jul; 20(7):815-826. PubMed ID: 33843379
[No Abstract] [Full Text] [Related]
11. European Medicines Agency review of post-authorisation studies with implications for the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.
Blake KV; Prilla S; Accadebled S; Guimier M; Biscaro M; Persson I; Arlett P; Blackburn S; Fitt H
Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1021-9. PubMed ID: 22039593
[TBL] [Abstract][Full Text] [Related]
12. Harmonization of Pharmacovigilance Regulation in Brazil: Opportunities to Improve Risk Communication.
Varallo FR; Forgerini M; Herdeiro MT; de Carvalho Mastroianni P
Clin Ther; 2019 Mar; 41(3):598-603. PubMed ID: 30792075
[TBL] [Abstract][Full Text] [Related]
13. A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012.
Farcas A; Balcescu T; Anghel L; Bucsa C; Mogoșan C
Expert Opin Drug Saf; 2020 Jun; 19(6):755-762. PubMed ID: 32186202
[TBL] [Abstract][Full Text] [Related]
14. Measuring the impact of the 2012 European pharmacovigilance legislation on additional risk minimization measures.
Francisca RDC; Zomerdijk IM; Sturkenboom MCJM; Straus SMJM
Expert Opin Drug Saf; 2018 Oct; 17(10):975-982. PubMed ID: 30107752
[TBL] [Abstract][Full Text] [Related]
15. Current state of biologic pharmacovigilance in the European Union: improvements are needed.
Felix T; Jordan JB; Akers C; Patel B; Drago D
Expert Opin Drug Saf; 2019 Mar; 18(3):231-240. PubMed ID: 30714424
[TBL] [Abstract][Full Text] [Related]
16. A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.
Tanti A; Micallef B; Serracino-Inglott A; Borg JJ
Expert Opin Drug Saf; 2017 Jan; 16(1):65-76. PubMed ID: 27732110
[TBL] [Abstract][Full Text] [Related]
17. [The new pharmacovigilance legislation in practice].
Broekmans AW; Mol PG
Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112
[TBL] [Abstract][Full Text] [Related]
18. European Union pharmacovigilance capabilities: potential for the new legislation.
Borg JJ; Tanti A; Kouvelas D; Lungu C; Pirozynski M; Serracino-Inglott A; Aislaitner G
Ther Adv Drug Saf; 2015 Aug; 6(4):120-40. PubMed ID: 26301067
[TBL] [Abstract][Full Text] [Related]
19. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
[TBL] [Abstract][Full Text] [Related]
20. New safety signals assessed by the Pharmacovigilance Risk Assessment Committee at EU level in 2014-2017.
Farcaş A; Măhălean A; Bulik NB; Leucuta D; Mogoșan C
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):1045-1051. PubMed ID: 30269618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
